Found: 21
Select item for more details and to access through your institution.
Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients' Quality of Life: a Prospective, Non-interventional Trial.
- Published in:
- Dermatology & Therapy, 2015, v. 5, n. 4, p. 217, doi. 10.1007/s13555-015-0089-y
- By:
- Publication type:
- Article
Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis.
- Published in:
- Allergy, Asthma & Clinical Immunology, 2020, v. 16, n. 1, p. 1, doi. 10.1186/s13223-020-00425-1
- By:
- Publication type:
- Article
Upregulation of Platelet-Activating Factor Receptor Expression and Lyso-Platelet-Activating Factor Isoforms in Human Nasal Polyp Tissues.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 23, p. 7357, doi. 10.3390/jcm12237357
- By:
- Publication type:
- Article
Rupatadine does not potentiate the CNS depressant effects of lorazepam: randomized, double-blind, crossover, repeated dose, placebo-controlled study.
- Published in:
- British Journal of Clinical Pharmacology, 2010, v. 69, n. 6, p. 663, doi. 10.1111/j.1365-2125.2010.03648.x
- By:
- Publication type:
- Article
No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a ‘thorough QT/QTc study’ performed according to ICH guidelines.
- Published in:
- British Journal of Clinical Pharmacology, 2010, v. 69, n. 4, p. 401, doi. 10.1111/j.1365-2125.2009.03599.x
- By:
- Publication type:
- Article
Clinically relevant effect of rupatadine 20 mg and 10 mg in seasonal allergic rhinitis: a pooled responder analysis.
- Published in:
- Clinical & Translational Allergy, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1186/s13601-019-0293-4
- By:
- Publication type:
- Article
Rupatadine oral solution for 2–5-year-old children with allergic rhinitis: a safety, open-label, prospective study.
- Published in:
- Journal of Asthma & Allergy, 2018, v. 11, p. 225, doi. 10.2147/JAA.S164632
- By:
- Publication type:
- Article
Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double-blind, placebo-controlled trial.
- Published in:
- Journal of Asthma & Allergy, 2011, v. 4, p. 27, doi. 10.2147/JAA.S18265
- By:
- Publication type:
- Article
Rupatadine Oral Solution Titration by Body Weight in Paediatric Patients Suffering from Allergic Rhinitis: A Population Pharmacokinetic Study.
- Published in:
- Clinical Pharmacology, 2021, v. 13, p. 115, doi. 10.2147/CPAA.S312911
- By:
- Publication type:
- Article
The impact of allergic rhinitis on symptoms, and quality of life using the new criterion of ARIA severity classification.
- Published in:
- Rhinology, 2012, v. 50, n. 1, p. 33, doi. 10.4193/rhino11.071
- By:
- Publication type:
- Article
Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Rupatadine 20 mg and 40 mg are Effective in Reducing the Symptoms of Chronic Cold Urticaria.
- Published in:
- Acta Dermato-Venereologica, 2016, v. 96, n. 1, p. 56, doi. 10.2340/00015555-2150
- By:
- Publication type:
- Article
Gastrointestinal safety of triflusal solution in healthy volunteers: a proof of concept endoscopic study.
- Published in:
- European Journal of Clinical Pharmacology, 2011, v. 67, n. 7, p. 663, doi. 10.1007/s00228-011-1004-9
- By:
- Publication type:
- Article
Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial.
- Published in:
- PLoS ONE, 2016, v. 11, n. 9, p. 1, doi. 10.1371/journal.pone.0163020
- By:
- Publication type:
- Article
Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2-11 years.
- Published in:
- Pediatric Allergy & Immunology, 2016, v. 27, n. 1, p. 55, doi. 10.1111/pai.12460
- By:
- Publication type:
- Article
Rupatadine oral solution in children with persistent allergic rhinitis: A randomized, double-blind, placebo-controlled study.
- Published in:
- Pediatric Allergy & Immunology, 2013, v. 24, n. 2, p. 144, doi. 10.1111/pai.12036
- By:
- Publication type:
- Article
Central and Peripheral Evaluation of Rupatadine, a New Antihistamine/Platelet-Activating Factor Antagonist, at Different Doses in Healthy Volunteers.
- Published in:
- Neuropsychobiology, 2004, v. 50, n. 4, p. 311, doi. 10.1159/000080959
- By:
- Publication type:
- Article
Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers.
- Published in:
- Human Psychopharmacology: Clinical & Experimental, 2006, v. 21, n. 1, p. 13, doi. 10.1002/hup.741
- By:
- Publication type:
- Article
New transcriptome and clinical findings of platelet‐activating factor in chronic spontaneous urticaria: Pathogenic and treatment relevance.
- Published in:
- Biofactors, 2022, v. 48, n. 6, p. 1284, doi. 10.1002/biof.1880
- By:
- Publication type:
- Article
Population pharmacokinetic modelling of rupatadine solution in 6–11 year olds and optimisation of the experimental design in younger children.
- Published in:
- PLoS ONE, 2017, v. 12, n. 4, p. 1, doi. 10.1371/journal.pone.0176091
- By:
- Publication type:
- Article